Moderna (NASDAQ: MRNA) awaits two decisions from the U.S. Food and Drug Administration. The company hopes to win full approval for its COVID-19 vaccine. It also wants the FDA to give a green light for a booster dose of its vaccine.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting